AKT1 and thyroid gland carcinoma: Indeed, exposure of thyroid cancer cell lines to AKT inhibitor B2311 drastically reduces H3K9ac and H3K4me3 levels, both transcription activation marks; and increases levels of H3K27me3, a well-known transcription repression mark, at the promoter of tumor suppressor tshr gene, leading to downregulation of tshr [197].